Pfizer/Pharmacia OTC Motion Sickness Stronghold Could Make FTC Queasy
This article was originally published in The Tan Sheet
Executive Summary
Pfizer's acquisition of Pharmacia likely will draw antitrust regulatory scrutiny to one of the combined firm's smallest product lines - OTC motion sickness tablets
You may also be interested in...
J&J Adds Cortaid, Insight Gets Bonine In Pfizer/Pharmacia Pre-Merger Sell Off
Johnson & Johnson will add Pharmacia's Cortaid OTC anti-itch and rash line to its skin remedies business in one of several divestitures planned to resolve Federal Trade Commission concerns regarding potential monopolies resulting from the merger of Pharmacia and Pfizer
J&J Adds Cortaid, Insight Gets Bonine In Pfizer/Pharmacia Pre-Merger Sell Off
Johnson & Johnson will add Pharmacia's Cortaid OTC anti-itch and rash line to its skin remedies business in one of several divestitures planned to resolve Federal Trade Commission concerns regarding potential monopolies resulting from the merger of Pharmacia and Pfizer
J&J Adds Cortaid, Insight Gets Bonine In Pfizer/Pharmacia Pre-Merger Sell Off
Johnson & Johnson will add Pharmacia's Cortaid OTC anti-itch and rash line to its skin remedies business in one of several divestitures planned to resolve Federal Trade Commission concerns regarding potential monopolies resulting from the merger of Pharmacia and Pfizer